<DOC>
	<DOCNO>NCT02328885</DOCNO>
	<brief_summary>Pilot , multicentric , open-label , single-arm , phase I-II clinical trial evaluate safety efficacy novel Umbilical Cord Blood Transplantation ( UCBT ) platform , consist UCBT 80 fraction , follow Donor Lymphocyte Infusion ( DLI ) 20 fraction ( 60 90 day transplantation ) .</brief_summary>
	<brief_title>Prophylactic Infusion Donor Lymphocytes Cord Blood Transplantation</brief_title>
	<detailed_description>Multicenter , open-label , single-arm , phase I-II pilot study mínimum 20 patient enter study primary objective ass safety secondary objective ass efficacy relation immune reconstituation follow new platform treatment consist initial cord blood unit 80 fraction transplantation , follow prophylactic donor lymphocite infusion ( DLI ) fraction 20 cord blood unit . The second infusion take place 60 90 day transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<criteria>At time transplantation : Patients 60 year proposal UCBT accord assistance protocol Diagnosis highrisk acute leukemia indication allogenic transplantation Frozen UCB bag split two bag : one 80 % product another 20 % Presence least 1.2E9 total nucleated cell &gt; 1E5 CD34 / kg &gt; 6E6 CD34 + fraction 80 % 4/6 good compatibility take Human Leukocyte Antigen ( HLA ) HLAA , HLAB antigenic resolution DRB1 allelic resolution The patient ( legal representative require ) sign informed consent At time DLI : Documented cord blood engraftment The patient ( Graft Versus Host Disease ) GVHD first 60 day posttransplantation , present , receive less 10 milligram prednisone time DLI &lt; 0.2 mg / kg / day prednisone pediatric patient ( &lt; 16 year ) . The patient le 200 CD4 + cell per microliter peripheral blood 60 day ( ± 7 day ) posttransplantation The patient ( legal representative require ) sign informed consent At time transplantation : Simultaneous participation another clinical trial treatment research phase product within 30 day prior inclusion study . Pregnant woman intend become pregnant within 12 month sign informed consent take proper contraceptive measure accord investigator criterion . Breastfeeding woman Other pathology circumstance may compromise patient 's participation study accord criterion investigator . At time DLI : Grade IIIIV GVHD allogeneic UCB Prednisone treatment ( &gt; 10 mg total per day adult &gt; 0.2 mg / kg / day prednisone pediatric patient )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>high-risk acute leukemia</keyword>
	<keyword>graft versus leukemia</keyword>
	<keyword>DLI</keyword>
	<keyword>UCBT</keyword>
</DOC>